Esophageal cancer
Conditions
Interventions
Patients without ctDNA decrease before and after the initial cycle of chemotherapy (post-/pre-ctDNA: equal or more than 10%): treatment change based on the efficacy evaluation of chemotherapy using co
Group C)
Sponsors
Division of Biomedical Research and Development, Institute of Biomedical Sciences, Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with Stage III/IV or recurrent esophageal cancer planning to chemotherapy with docetaxel, cisplatin and 5-FU or CDDP and 5-FU as the first line therapy 2) Histologically diagnosed esophageal carcinoma 3) Primary tumor located in thoracic esophagus. Tumor which is centrally located more than 2 cm below of the esophago-gastric junction is ineligible 4) ECOG performance status: 0-2 5) More than 2 treatments regimens are remained 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Synchronous malignancies except for early cancer which will not affect prognosis. 2) Patients with active infection with fever requiring a systematic therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year overall survival rates | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Progression free survival rates 2) ctDNA dynamics and change of tumor burden 3) Quality of life, Quality-adjusted life years | — |
Countries
Japan
Contacts
Public ContactTakeshi Iwaya
Iwate Medical University School of Medicine Department of Surgery
Outcome results
None listed